|
![]() |
|
|
Felodipine
drug data and news
Felodipine drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Felodipine | ||
| Brand Names/Synonyms | AGON SR; Agon; CHEMBANK1781; Dl-Felodipine; FEXOFENADINE HCL; Faropenem; Feloday; Felodipina [Inn-Spanish]; Felodipine; Felodipine [Usan:Ban:Inn]; Felodipinum [Inn-Latin]; Felodur Er; Felogard; Fexofenadine Hydrochloride; Fexofinadine Hcl; Flodil; H 154/82; H-154/82; Hydac; Lexxel; Modip; Munobal; Munobal Retard; Penedil; Perfudal; Plandil; Plendil; Plendil Depottab; Plendil Er; Plendil Retard; Preslow; Prevex; Renedil; Splendil | ||
| Indication | For the treatment of hypertension | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Felodipine, a dihydropyridine calcium-channel blocker, is used alone or with an angiotensin-converting enzyme inhibitor, to treat hypertension, chronic stable angina pectoris, and Prinzmetal's variant angina. Felodipine is similar to other peripheral vasodilators. Felodipine inhibits the influx of extra cellular calcium across the myocardial and vascular smooth muscle cell membranes blocking the calcium channels. The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload. | ||
| Mechanism Of Action | Felodipine is Ca++ channel blocker. It reversibly competes with nitrendipine and/or other calcium channel blockers for dihydropyridine binding sites, blocks voltage-dependent Ca++ currents in vascular smooth muscle and cultured rabbit atrial cells, and blocks potassium- induced contracture of the rat portal vein. By blocker the Ca++ channels, Felodipine inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes and results in a decrease of peripheral vascular resistance. | ||
| Felodipine News (When available) |
Reduce platelet aggregation, blood clotting, inflammation, nervous ... Jan 12, 2006 Heart medicines cheaper Nov 30, 2005 Full funding for cardiac treatments Nov 29, 2005 AstraZeneca Provides Additional Support to Hurricane Victims Nov 17, 2005 AstraZeneca Provides Additional Support to Hurricane Victims Nov 17, 2005 URL/Mutual Tracking to Achieve Another Record Year in Sales ... Sep 12, 2005 AstraZeneca Pledges More Than $1 Million in Contributions and ... Sep 1, 2005 AstraZeneca Pledges More Than $1 Million in Contributions and ... Sep 1, 2005 Many Filipinos diabetic and hypertensive Aug 12, 2005 Common germ uncommonly causes death Jun 2, 2005 Grapefruit and Prescription Drugs: Mix Carefully Mar 29, 2005 Dunne maintains PHARMAC attack Apr 5, 2005 Drugs to combat hypertension Apr 12, 2005 Non-diabetic proteinuric nephropathies, add-on therapy provides no ... Mar 11, 2005 Neophyte solon bares drug cartel Mar 2, 2005 Management of Hypertension in Older Persons Feb 21, 2005 | ||
| Dosage Forms | Oral tablets | ||
| Drug_Category | Vasodilator Agents; Antihypertensive Agents; Antiarrhythmic Agents; Dihydropyridines; ATC:C08CA02 | ||
| Absorption | 15% | ||
| Interactions |
-->Interactions for Felodipine: CYP3A4 Inhibitors—Felodipine is metabolized by CYP3A4. Co-administration of CYP3A4 inhibitors (eg, ketoconazole, itraconazole, erythromycin, grapefruit juice, cimetidine) with felodipine may lead to several- fold increases in the plasma levels of felodipine, either due to an increase in bioavailability or due to a decrease in metabolism. These increases in concentration may lead to increased effects, (lower blood pressure and increased heart rate). These effects have been observed with co-administration of itraconazole (a potent CYP3A4 inhibitor). Caution should be used when CYP3A4 inhibitors are co-administered with felodipine. A conservative approach to dosing felodipine should be taken. The following specific interactions have been reported: Itraconazole—Co-administration of another extended release formulation of felodipine with itraconazole resulted in approximately 8-fold increase in the AUC, more than 6- fold increase in the Cmax, and 2-fold prolongation in the half- life of felodipine. Erythromycin—Co-administration of felodipine (PLENDIL) with erythromycin resulted in approximately 2.5- fold increase in the AUC and Cmax, and about 2- fold prolongation in the half- life of felodipine. Grapefruit juice—Co-administration of felodipine with grapefruit juice resulted in more than 2-fold increase in the AUC and Cmax, but no prolongation in the half- life of felodipine. Cimetidine—Co-administration of felodipine with cimetidine (a non-specific CYP-450 inhibitor) resulted in an increase of approximately 50% in the AUC and the Cmax, of felodipine. Beta-Blocking Agents— A pharmacokinetic study of felodipine in conjunction with metoprolol demonstrated no significant effects on the pharmacokinetics of felodipine. The AUC and Cmax of metoprolol, however, were increased approximately 31 and 38%, respectively. In controlled clinical trials, however, beta blockers including metoprolol were concurrently administered with felodipine and were well tolerated. Digoxin— When given concomitantly with PLENDIL the pharmacokinetics of digoxin in patients with heart failure were not significantly altered. Anticonvulsants— In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers. In such patients, the mean area under the felodipine plasma concentration-time curve was also reduced to approximately 6% of that observed in healthy volunteers. Since a clinically significant interaction may be anticipated, alternative antihypertensive therapy should be considered in these patients. Tacrolimus— Felodipine may increase the blood concentration of tacrolimus. When given concomitantly with felodipine, the tacrolimus blood concentration should be followed and the tacrolimus dose may need to be adjusted. Other Concomitant Therapy— In healthy subjects there were no clinically significant interactions when felodipine was given concomitantly with indomethacin or spironolactone. Interaction with Food— See CLINICAL PHARMACOLOGY, Pharmacokinetics and Metabolism. | ||
| Toxicity | excessive peripheral vasodilation with marked hypotension and possibly bradycardia | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | methylethyl4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate | ||
| Chemical Formula | C18H19Cl2NO4 | ||
| Molecular Weight | 384.253 g/mol | ||
| Smiles String | CCOC(=O)C1=C(NC(=C(C1C2=C(C(=CC=C2)Cl)Cl)C(=O)OC)C)C | ||
| Melting Point | 145°C | ||
| Water Solubility | 19.7 mg/L | ||
| State | slightly yellowish, crystalline powder | ||
| LogP/Hphobicity | 4.121 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Hepatic | ||
| Half Life | 14.1 hours | ||
| Protein Binding [%] | 99% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Felodipine.html http://www.rxlist.com/cgi/generic2/felo.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00374 | ||
| CAS Registry Number | 72509-76-3 | ||
| KEGG Compound ID | C06995 | ||
| PubChem ID | SID:189780 | ||
| PharmGKB ID | Not Available | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2222000 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |